Brief: CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug Application For CID-103 In Immune Thrombocytopenia
15/05/2024 13:25
May 15 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS RECEIVES FDA CLEARANCE ON THE
INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CID-103 IN IMMUNE
THROMBOCYTOPENIA (ITP)
* CASI PHARMACEUTICALS INC: ON MAY 13, 2024 CASI RECEIVED A
LETTER
FROM FDA INDICATING THAT STUDY MAY PROCEED
Source text for Eikon: ID:nPn3QRtR3a
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary